Vertex’s CF drugs drive 18% growth as company looks to diversify

One of Boston’s largest pharmaceutical companies, Vertex Pharmaceuticals is growing significantly — but its revenues are still tied to its cystic fibrosis (CF) portfolio, and as CEO Reshma Kewalramani highlighted on Thursday’s earnings call, that will soon need to change. "You have never seen us invest more in our internal innovation," she said.